UBS backs senior housing REITs ahead of summer earnings

UBS backs senior housing REITs ahead of summer earnings
UBS bets on senior housing

Demographic growth and tight new supply are supporting senior housing and skilled nursing landlords as the sector heads into the summer earnings season. UBS says these real estate investment trusts also benefit from acquisition conditions that could lift earnings while continuing to offer dividend income.

Highlights

  • UBS analyst Michael Goldsmith highlights strong demand and limited supply for senior housing, with NIC MAP data showing Q2 occupancy near 90% and population aged 80+ expected to reach 23 million by 2035.
  • Goldsmith raises price targets on American Healthcare REIT to $63 (from $60) and Welltower to $271 (from $249), citing growth drivers and equity raises, while maintaining targets for CareTrust ($48) and Omega Healthcare Investors ($54).
  • 2026 core FFO forecasts: American Healthcare REIT at $2.10/share (above $2.07 consensus), Welltower at $6.27/share, CareTrust at $2.04/share, Omega Healthcare Investors at $3.25/share, with all stocks up 9-24% YTD.

Sector outlook and earnings setup

As reported by CNBC, UBS analyst Michael Goldsmith says investors should expect favorable updates when senior housing and skilled nursing companies publish their latest results this summer, helped by solid operating fundamentals and accretive acquisitions.

Goldsmith says senior housing continues to benefit from muted supply growth and demographic tailwinds. He adds that recent conference commentary indicates new development projects largely remain uneconomic at current rental rates, reinforcing expectations for limited future supply.

The U.S. population shift is adding to that backdrop as baby boomers age and fertility rates decline. The first baby boomers begin turning 80 this year, and the population aged 80 and above is expected to reach nearly 23 million by 2035, up from about 15 million in the July 2025 estimate. Demand is now outpacing construction of new senior housing units, while second-quarter occupancy nears 90%, according to NIC MAP data released Thursday.

Preferred REIT names and upside potential

UBS has buy ratings on American Healthcare REIT, CareTrust REIT, Omega Healthcare Investors and Welltower. Goldsmith raises his price target on American Healthcare REIT to $63 from $60 and on Welltower to $271 from $249, while maintaining targets of $48 for CareTrust and $54 for Omega Healthcare Investors.

For American Healthcare REIT, Goldsmith says external growth remains a major earnings driver. He notes the company recently raises about $700 million in equity to fund an awarded SHOP pipeline exceeding $1 billion, and he estimates 2026 core funds from operations at $2.10 per share, above the $2.07 consensus; the stock is up 13% so far this year and is expected to report second-quarter results on Aug. 6.

Welltower is expected to report earnings on July 27. Goldsmith says the new target reflects similar or slightly better growth trends, a continued shift toward more operating assets, improvements to the Welltower Business System and a better cost of capital; he forecasts 2026 core FFO at $6.27 per share versus a $6.29 consensus, while the stock has gained 24% year to date.

CareTrust, which yields 3.88%, is benefiting more from its expansion into care homes in the UK as well as senior housing, Goldsmith says. He expects its next earnings report in early August and forecasts 2026 core FFO at $2.04 per share, in line with consensus.

For Omega Healthcare Investors, Goldsmith forecasts full-year 2026 core FFO at $3.25 per share, compared with a $3.26 consensus estimate. The company, which has a dividend yield of 5.57% and is due to report on July 30, has risen 9% so far in 2026, while CareTrust shares are up 11%.

Our earlier article on the upcoming earnings season highlighted companies with strong records of beating Wall Street estimates and often seeing shares rise after results, pointing to names investors tend to watch closely into reports. We also noted analyst support around select stocks and discussed how scheduled releases can act as near-term catalysts that shape broader market sentiment early in the season.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.